Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...

oNet Registry Update March 2005
dverse Events/Side Effects (AE) and Vascular Access Problems (VAP) (VAP)
Stratified by Experience of Rheopheresis Center (international)
E/SE
ll indications
20,0
8,3
2,1
10,4
3,8
1,3
6,4
2,0 0,5
2,4 1,4 0,4
n < 20 n = 20-100 n = 100-1000 n > 1000
20 centers
Ø7
treatments
Class I Class II Class III %
9 centers
Ø 44
treatments
8 centers
Ø 267
treatments
1 center
1579
treatments
50
40
30
20
10
0
VAP
All indications
30,4
17,4
9,4
Class I Class II Class III
17,2
5,8 4,0
7,3
1,9 1,1
1,5 0,3 0,1
n < 20 n = 20-100 n = 100-1000 n > 1000
20 centers
Ø7
treatments
n = number of treatments
9 centers
Ø 44
treatments
8 centers
Ø 267
treatments
1 center
1579
treatments